Founder, President & CEO Douglas P. Hatran has produced two (2) CE Marked devices & one (1) FDA.PMA-2017, Co-creator/Developer of Stellarex (now owned by Spectranetics). Doug worked among the founding members of RIGEL Pharmaceuticals Inc. (RIGL IPO.2000) and helped start Zystor Therapeutics (acquired by Biomarin). Doug is co-published in AJP, J.OB/Gyn, & Journal Physiology London.


Co-Founder Samuel K. Chong holds degrees in both Physics and Mathematics. He has worked in both pre-clinical and manufacturing settings in Industry and Academia with broad experience in medical applications. Over the past 8 years he has focused on analytical chemistry and has supported projects from conception to phase III FDA applications.